Table 4.
Survival from symptom onset (time point T0)
| Parameter | NIV status | Stratification | n | Mean survival (months) | Median survival (months) | p |
|---|---|---|---|---|---|---|
| AHI | NIV(+) | < 5/h | 40 | 46.1 (26.2) | 41.6 (9.6–128.2) | n.s. |
| ≥ 5/h | 55 | 54.1 (34.1) | 48.7 (6.0–173.1) | |||
| NIV(−) | < 5/h | 38 | 51.0 (40.1) | 42.2 (14.3–223.0) | n.s. | |
| ≥ 5/h | 25 | 60.5 (67.5) | 36.2 (10.1–341.1) | |||
| max. ptcCO2 | NIV(+) | < 50 mmHg | 59 | 54.0 (34.6) | 47.0 (6.0–173.1) | n.s. |
| ≥ 50 mmHg | 36 | 45.4 (23.9) | 423 (9.6–104.4) | |||
| NIV(–) | < 50 mmHg | 59 | 56.7 (53.5) | 42.0 (10.1–341.1) | n.s. | |
| ≥ 50 mmHg | 4 | 25.6 (10.2) | 23.6 (16.0–39.2) | |||
| ≥ 50 | NIV(+) | < 30 min | 72 | 52.0 (32.1) | 47.0 (6.0–173.1) | n.s. |
| ≥ 30 min | 17 | 44.9 (22.2) | 42.0 (14.0–99.2) | |||
| NIV(−) | < 30 min | 63 | 54.8 (52.4) | 39.1 (10.1–341.1) | – | |
| ≥ 30 min | 0 | |||||
| EMBE | NIV(+) | ≤ 2 mmol/l | 36 | 58.2 (36.9) | 47.9 (6.0–173.1) | n.s. |
| > 2 mmol/l | 52 | 43.2 (23.7) | 41.5 (9.6–128.1) | |||
| NIV(–) | ≤ 2 mmol/l | 30 | 67.7 (61.8) | 49.5 (14.3–341.1) | 0.007 | |
| > 2 mmol/l | 28 | 41.5 (39.5) | 29.4 (10.1–223.0) | |||
| upright FVC | NIV(+) | ≥ 70% pred | 25 | 51.0 (32.2) | 46.9 (6.0–128.1) | n.s. |
| < 70% pred | 35 | 52.8 (34.5) | 48.7 (9.6–173.1) | |||
| NIV(−) | ≥ 70% pred | 26 | 47.1 (34.5) | 38.0 (10.1–144.2) | n.s. | |
| < 70% pred | 11 | 48.2 (27.7) | 42.0 (16.0–117.1) |
Patients were stratified according to baseline respiratory sleep outcomes (using specific cut-off values) and NIV status. Mean survival is depicted in column 5, with standard deviation in brackets. Median survival is shown in column 6 (with range in brackets)
EMBE early morning base excess, FVC forced vital capacity, AHI apnea hypopnea index, ptcCO2 maximum transcutaneous carbon dioxide tension, ≥ 50 cumulative duration of nocturnal hypercapnia ≥ 50 mmHg
p values in the last column refer to the Mann–Whitney U test